Hrvatska znanstvena Sekcija img
3 gif
 O projektu
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 495839

Zbornik radova

Autori: Užarević, Zvonimir; Sabol, Maja; Car, Diana; Ozretić, Petar; Musani, Vesna; Bogut, Irella; Levanat, Sonja
Naslov: Hh-Gli signaling pathway activity in ER-positive (MCF-7) and ER-negative (Sk-Br-3) breast cancer cell lines treated with tamoxifen
( Hh-Gli signaling pathway activity in ER-positive (MCF-7) and ER-negative (Sk-Br-3) breast cancer cell lines treated with tamoxifen )
Izvornik: Book of Abstracts of the First meeting of the Croatian Association for Cancer Research with international participation HDIR-1 „From Bench to Clinic“ / Sabol, Maja ; Levanat, Sonja (ur.). - Zagreb : Hrvatsko društvo za istraživanje raka (HDIR) , 2010. 35-35.
Skup: HDIR-1 - First Meeting with International Participation: „From Bench to Clinic“
Mjesto i datum: Zagreb, Hrvatska, 11.11.2010.
Ključne riječi: Hh-Gli signaling pathway ; breast cancer ; tamoxifen ; cyclopamine
( Hh-Gli signaling pathway ; breast cancer ; tamoxifen ; cyclopamine )
Hedgehog-Gli (Hh-Gli) signaling pathway regulates a wide variety of processes during embryonic development and adult tissue homeostasis, and its malfunctioning is often associated with tumorigenesis and developmental malformations. Activation of Hh-Gli signaling has been reported in about 30% of human cancers including breast cancer. The ligand protein Sonic Hedhegog (Shh) binds to the transmembrane receptor Patched (Ptch). Ptch then releases its inhibition of Smoothened (Smo), and a cytoplasmatic cascade of phosphorylation and dephosphorylation events leading to activation of transcription factor Gli and transcription of target genes, which include Cyclin D, Cyclin E, members of Wnt and TGFβ signaling pathways, and Ptch itself. Tamoxifen inhibits proliferation and induces apoptosis of breast cancer cells by estrogen receptor (ER)-dependent modulation of gene expression. In this work we focus our interest on human breast cancer cell lines, ER-positive (MCF-7) and ER-negative (Sk-Br-3), where we intend to see how Hh-Gli signaling pathway is expressed in cell lines treated with tamoxifen. Also, we are interested in potential therapeutical application of a known pathway inhibitor cyclopamine in combination with tamoxifen, whose activities we intend to test on these cells. Using MTT assay to determine cell viability we observed that tamoxifen induced rapid death in both ER-positive (MCF-7) and ER-negative (Sk-Br-3) breast cancer cell lines. Combined treatment with cyclopamine and tamoxifen differred between the tested cell lines, and the reactivity to these drugs is dependant on the order in which they are administered. Real-Time PCR demonstrated variable expression of the Hh-Gli pathway genes (SHH, PTCH, GLI1, SMO and SUFU). Western blot analysis shows difference in protein expression of main members of the pathway (Ptch, Smo, Shh and Gli1). Our preliminary results suggest Hh-Gli pathway involvement in tumorigenesis in tested cancer cell lines with variable intensity and that tamoxifen resulted rapid cell death in both investigated cancer cell lines, alone or in combination with cyclopamine. Those results gave a promising model for further studies as an effective strategy for cancer treatment.
Vrsta sudjelovanja: Poster
Vrsta prezentacije u zborniku: Sažetak
Vrsta recenzije: Domaća recenzija
Projekt / tema: 245-0000000-3613, 098-0982464-2461
Izvorni jezik: eng
Kategorija: Znanstveni
Znanstvena područja:
Temeljne medicinske znanosti
Upisao u CROSBI: (, 22. Pro. 2010. u 00:29 sati

Verzija za printanje   za tiskati